The effect of cyclooxygenase-2 overexpression on skin carcinogenesis is context dependent

Molecular Carcinogenesis

Volumn 46, Issue 12, 2007, Pages 981-992

  Rundhaug, Joyce E ^a   Pavone, Amy ^a   Kim, Eunjung ^a,b   Fischer, Susan M ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

COX 2; Prostaglandins; Skin carcinogenesis

Indexed keywords

7,12 DIMETHYLBENZ[A]ANTHRACENE; CYCLOOXYGENASE 2; CYTOKERATIN 14; DIMETHYLBENZ[A]ANTHRACENE; DITHRANOL; INTERLEUKIN 1ALPHA; ORNITHINE DECARBOXYLASE; PHORBOL DIACETATE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CONTROLLED STUDY; EPIDERMIS; EPIDERMIS CELL; GENE EXPRESSION; GENETIC TRANSCRIPTION; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SKIN CARCINOGENESIS; TRANSGENIC MOUSE; TUMOR PROMOTION; UPREGULATION;

9,10-DIMETHYL-1,2-BENZANTHRACENE; ANIMALS; ANTHRALIN; BLOTTING, NORTHERN; BLOTTING, WESTERN; CARCINOGENS; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; CYCLIC AMP; CYCLIC AMP RESPONSE ELEMENT-BINDING PROTEIN; CYCLOOXYGENASE 2; DERMATOLOGIC AGENTS; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; INTERLEUKIN-1ALPHA; MICE; MICE, TRANSGENIC; ORNITHINE DECARBOXYLASE; SKIN NEOPLASMS; TETRADECANOYLPHORBOL ACETATE; TUMOR NECROSIS FACTOR-ALPHA;

MUS; MUS MUSCULUS;

EID: 36849036243     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.20340     Document Type: Article

References (53)

1. Xie W, Herschman HR. v-src induces prostaglandin synthase 2 gene expression by activation of c-Jun N-terminal kinase and the c-Jun transcription factor. J Biol Chem 1995;270:27622-27628.
2. Smith WL, DeWitt DL, Garavito RM. Cyclooxygenases: Structural, cellular, and molecular biology. Ann Rev Biochem 2000;69:145-182.
3. Chandrasekharan NV, Dai H, Roos KLT, et al. COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: Cloning, structure, and expression. Proc Natl Acad Sei USA 2002;99:13926-13931.
4. Müller-Decker K, Scholz K, Marks F, Fürstenberger G. Differential expression of prostaglandin H synthase isozymes during multistage carcinogenesis in mouse epidermis. Mol Carcinog 1995;12:31-41.
5. Sano H, Kawahito Y, Wilder RL, et al. Expression of cyclooxygenase-1 and -2 in human colorectal cancer. Cancer Res 1995;55:3785-3789.
6. Gustafson-Svard C, Lilja I, Hallbook O, Sjodahl R. Cyclooxygenase-1 and cyclooxygenase-2 gene expression in human colorectal adenocarcinomas and in azoxymethane induced colonic tumours in rats. Gut 1996;38:79-84.
7. Hida T, Yatabe Y, Achiwa H, et al. Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically adenocarcinomas. Cancer Res 1998;58:3761-3764.
8. Parrett ML, Harris RE, Joarder FS, Ross MS, Clausen KF, Robertson FM. Cyclooxygenase-2 gene expression in human breast cancer. Int J Oncol 1997;10:503-507.
9. Yoshimura R, Sano H, Masuda C, et al. Expression of cyclooxygenase-2 in prostate carcinoma. Cancer 2000;89:589-596.
10. Fischer SM, Lo H-H, Gordon GB, et al. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, and indomethacin against ultraviolet light-induced skin carcinogenesis. Mol Carcinog 1999;25:231-240.
11. DuBois RN, Radhika A, Reddy BS, Entingh AJ. Increased cyclooxygenase-2 levels in carcinogen-induced rat colonic tumors. Gastroenterol 1996;110:1259-1262.
12. Williams CS, Luongo C, Radhika A, et al. Elevated cyclooxygenase-2 levels in Min mouse adenomas. Gastroenterol 1996;111:1134-1140.
13. Subbaramaiah K, Dannenberg AJ. Cyclooxygenase 2: A molecular target for cancer prevention and treatment. Trends Pharmacol Sci 2003;24:96-102.
14. Δ716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 1996;87:803-809.
15. Kawamori T, Rao CV, Seibert K, Reddy BS. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. Cancer Res 1998;58:409-412.
16. Reddy BS, Rao CV, Seibert K. Evaluation of cyclooxygenase-2 inhibitor for potential chemopreventive properties in colon carcinogenesis. Cancer Res 1996;56:4566-4569.
17. Maier TJ, Schilling K, Schmidt R, Geisslinger G, Grösch S. Cyclooxygenase-2 (COX-2)-dependent and -independent anticarcinogenic effects of celecoxib in human colon carcinoma cells. Biochem Pharmacol 2004;67:1469-1478.
18. Shureiqi I, Chen D, Lotan R, et al. 15-Lipoxygenase-1 mediates nonsteroidal anti-inflammatory drug-induced apoptosis independently of cyclooxygenase-2 in colon cancer cells. Cancer Res 2000;60:6846-6850.
19. Zhang X, Morham SG, Langenbach R, Young DA. Malignant transformation and antineoplastic actions of nonsteroidal antiinflammatory drugs (NSAIDs) on cyclooxygenase-null embryo fibroblasts. J Exp Med 1999;190:451-459.
20. Hanif R, Pittas A, Feng Y, et al. Effects of nonsteroidal antiinflammatory drugs on proliferation and on induction of apoptosis in colon cancer cells by a prostaglandin-independent pathway. Biochem Pharmacol 1996;52:237-245.
21. Piazza GA, Alberts DS, Hixson U, et al. Sulindac sulfone inhibits azoxymethane-induced colon carcinogenesis in rats without reducing prostaglandin levels. Cancer Res 1997;57:2909-2915.
22. Thompson HJ, Jiang C, Lu J, et al. Sulfone metabolite of sulindac inhibits mammary carcinogenesis. Cancer Res 1997;57:267-271.
23. Stoner GD, Budd GT, Ganapathi R, et al. Sulindac sulfone induced regression of rectal polyps in patients with familial adenomatous polyposis. Adv Exp Med Biol 1999;470:45-53.
24. Tiano HF, Loftin CD, Akunda J, et al. Deficiency of either cyclooxygenase (COX)-1 or COX-2 alters epidermal differentiation and reduces mouse skin tumorigenesis. Cancer Res 2002;62:3395-3401.
25. Liu CH, Chang S-H, Narko K, et al. Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice. J Biol Chem 2001;276:18563-18569.
26. Müller-Decker K, Neufang G, Berger I, Neumann M, Marks F, Fürstenberger G. Transgenic cyclooxygenase-2 overexpression sensitizes mouse skin for carcinogenesis. Proc Natl Acad Sci USA 2002;99:12483-12488.
27. Bol DK, Rowley RB, Ho C-P, et al. Cyclooxygenase-2 overexpression in the skin of transgenic mice results in suppression of tumor development. Cancer Res 2002;62:2516-2521.
28. Maldve RE, Fischer SM. Multifactor regulation of prostaglandin H synthase-2 in murine keratinocytes. Molec Carcinog 1996;17:207-216.
29. Müller-Decker K, Kopp-Schneider A, Marks F, Seibert K, Fürstenberger G. Localization of prostaglandin H synthase isoenzymes in murine epidermal tumors: Suppression of skin tumor promotion by inhibition of prostaglandin H synthase-2. Mol Carcinog 1998;23:36-44.
30. DiGiovanni J, Kruszewski FH, Coombs MM, Bhatt TS, Pezeshk A. Structure-activity relationships for epidermal ornithine decarboxylase induction and skin tumor promotion byanthrones. Carcinogenesis 1988;9:1437-1443.
31. Tsuboi K, Sugimoto Y, Ichikawa A. Prostanoid receptor subtypes. Prostaglandins Other Lipid Mediat 2002. 68-69:535-556.
32. Fischer SM. Cellular and molecular mechanisms of tumor promotion. In: Bowden GT, Fischer SM, editors. Chemical Carcinogens and Anticarcinogens. Volume 12, Comprehensive Toxicology. New York: Elsevier 1997. pp 349-381.
33. Dawson MI, Chao W-R, Helmes CT. Inhibition by retinoids of anthralin-induced mouse epidermal ornithine decarboxylase activity and anthralin-promoted skin tumor formation. Cancer Res 1987;47:6210-6215.
34. Gilmour SK, Verma AK, Madara T, O'Brien TG. Regulation of ornithine decarboxylase gene expression in mouse epidermis and epidermal tumors during two-stage tumorigenesis. Cancer Res 1987;47:1221-1225.
35. Moore RJ, Owens DM, Stamp G, et al. Mice deficient in tumor necrosis factor-α are resistant to skin carcinogenesis. Nat Med 1999;5:828-831.
36. Suganuma M, Okabe S, Marino MW, Sakai A, Sueoka E, Fujiki H. Essential role of tumor necrosis α (TNF-α) in tumor promotion as revealed by TNF-α-deficient mice. Cancer Res 1999;59:4516-4518.
37. Starcher B. Role for tumour necrosis factor-α receptors in ultraviolet-induced skin tumors. Brit J Dermatol 2000;142:1140-1147.
38. Wheeler DL, Ness KJ, Oberley TD, Verma AK. Protein kinase Cε is linked to 12-O-tetradecanoylphorbol-13-acetate-induced tumor necrosis factor-α ectodomain shedding and the development of metastatic squamous cell carcinoma in protein kinase Cε transgenic mice. Cancer Res 2003;63:6547-6555.
39. Fischer SM, Jasheway DW, Klann RC, et al. Correlation of phorbol ester promotion in the resistant C57BL/6 J mouse with sustained hyperplasia but not ornithine decarboxylase or protein kinase C. Cancer Res 1989;49:6693-6699.
40. Dong Z, Birrer MJ, Watts RG, Matrisian LM, Colburn NH. Blocking of tumor promoter-induced AP-1 activity inhibits induced transformation in JB6 mouse epidermal cells. Proc Natl Acad Sci USA 1994;91:609-613.
41. Young MR, Li J-J, Rincon M, et al. Transgenic mice demonstrate AP-1 (activator protein-1) transactivation is required for tumor promotion. Proc Natl Acad Sci, USA 1999;96:9827-9832.
42. Karin M. The regulation of AP-1 activity by mitogen-activated protein kinases. J Biol Chem 1995;270:16483-16486.
43. Karin M, Smeal T. Control of transcription factors by signal transduction pathways: The beginning of the end. Trends Biochem Sci 1992;17:418-422.
44. Fischer SM, Pavone A, Mikulec C, Langenbach R, Rundhaug JE. Cyclooxygenase-2 expression is critical for chronic UV-induced murine skin carcinogenesis. Mol Carcinog 2007;46:doi 10.1002/mc.20284.
45. Neufang G, Fürstenberger G, Heidt M, Marks F, Müller-Decker K. Abnormal differentiation of epidermis in transgenic mice constitutively expressing cyclooxygenase-2 in skin. Proc Natl Acad Sci USA 2001;98:7629-7634.
46. Fischer SM, Fürstenberger G, Marks F, Slaga TJ. Events associated with mouse skin tumor promotion with respect to arachidonic acid metabolism: A comparison between SENCAR and NMRI mice. Cancer Res 1987;47:3174-3179.
47. Fischer SM, Gleason GL, Hardin LG, Bohrman JS, Slaga TJ. Prostaglandin modulation of phorbol ester skin tumor promotion. Carcinogenesis 1980;1:245-248.
48. Sung YM, He G, Fischer SM. Lack of expression of the EP2 but not EP3 receptor for prostaglandin E2 results in suppression of skin tumor development. Cancer Res 2005;65:9304-9311.
49. Perchellet J-P, Boutwell RK. Effects of 3-isobutyl-1-methylxanthine and cyclic nucleotides on the biochemical processes linked to skin tumor promotion by 12-O-tetradecanoylphorbol-13-acetate. Cancer Res 1981;41:3927-3935.
50. Perchellet J-P, Boutwell RK. Comparison of the effects of 3-isobutyl-1-methylxanthine and adenosine cyclic 3′:5′-monophosphate on the induction of skin tumors by the initiation-promotion protocol and by the complete carcinogenesis process. Carcinogenesis 1982;3:53-60.
51. Montminy M. Transcriptional regulation by cyclic AMP. Ann Rev Biochem 1997;66:807-822.
52. Fischer S, DiGiovanni J. Mechanisms of tumor promotion: Epigenetic changes in cell signaling. Cancer Bull 1995;47:456-463.
53. Lee WY, Locniskar MF, Fischer SM. Interleukin-1α mediates phorbol ester-induced inflammation and epdiermal hyperplasia. FASEB J 1994;8:1081-1087.